Article thumbnail
Location of Repository

Involvement of kainate glutamate receptors in the modulation of neuronal transmission in brain areas involved in migraine pathophysiology

By A. Andreou


Migraine pathophysiology is thought to involve activation of the trigeminal fibres which innervate dural structures. The nociceptive inflow from the meninges is relayed to the trigeminocervical complex (TCC), before ascending to higher brain areas, including the thalamus. Glutamate is implicated in the transmission of the nociceptive information and thus an increased understanding of the nature and effects of glutamate receptors activation has major implications in migraine pathophysiology and treatment. Here the role of kainate receptors, a member of the ionotropic glutamate receptors subfamily, was investigated in relaying sensory information upon activation of the trigeminovascular system. In order to study the role of kainate receptors on the periphery, we used the neurogenic dural vasodilation (NDV) model, in which electrical stimulation of the dura mater causes reproducible vasodilation, due to calcitonic gene-related peptide (CGRP) release. In this set of experiments kainate receptor activation but not blockade was effective in inhibiting NDV. Vasodilation induced by systemic administration of CGRP was not changed by administration of a kainate receptor agonist. In the TCC, local application by microiontophoresis of a selective kainate receptor antagonist on second order neurons which were excited by meningeal electrical stimulation, caused dual effects; 50% of the neurons tested were inhibited, whereas in a second subpopulation, activation in response to meningeal stimulation was facilitated. However, in all neurons tested, post-synaptic activation in response to kainate receptor agonists application was selectively inhibited. Microiontophoretic ejection of a kainate receptor antagonist in the ventroposteromedial thalamus (VPM) was able to inhibit cell firing in response to dural stimulation, as well as post-synaptic firing in response to kainate receptor activation. Both effects were reversed when the kainate receptor antagonist was co-ejected with a 5-HT1B receptor antagonist. We also carried electrophysiology studies in both the TCC and the VPM nucleus in order to compare the effects of the clinically active kainate receptor antagonist LY466195. Systemic and local application of LY466195 was able to inhibit cell firing in response to dura mater stimulation in both the TCC and VPM nucleus. Moreover, further to the kainate binding, a significant action of the compound on N-methyl-Daspartate receptors was observed

Publisher: UCL (University College London)
Year: 2009
OAI identifier:
Provided by: UCL Discovery

Suggested articles


  1. (2005a) New targets in the acute treatment of headache.
  2. (2005b) Advances in the understanding of headache.
  3. (2005c) Migraine, allodynia, sensitisation and all of that.
  4. (1998). (R)-(+)-2-[[[3-(Morpholinomethyl)-2H-chromen-8-yl]oxy]methyl] morpholine methanesulfonate: a new selective rat 5-hydroxytryptamine1B receptor antagonist.
  5. (1993). (S)-N-tert-butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamid e [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors.
  6. (2004). [Innovative treatment of acute migraine pain with CGRP receptor antagonists].
  7. (2001). 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase.
  8. (1993). 5-HT1-like receptors: six down and still counting.
  9. (2004). A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression.
  10. (1988). A combined recording and microiontophoresis technique for input-output analysis of single neurons in the mammalian CNS.
  11. (1993). A complex mosaic of high-affinity kainate receptors in rat brain.
  12. (1934). A contribution to the mechanism of intracranial pain.
  13. (1996). A nosographic analysis of the migraine aura in a general population.
  14. (1997). A pharmacological and clinical review on topiramate, a new antiepileptic drug.
  15. (1989). A quantitative study of the projections of the gracile, cuneate and trigeminal nuclei and of the medullary reticular formation to the thalamus in the rat.
  16. (1997). A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases.
  17. (2003). A role for extracellular Na+ in the channel gating of native and recombinant kainate receptors.
  18. (1978). A study of sensory projection from jaw muscles to the cerebral cortex in the rat.
  19. (2004). Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception.
  20. (1999). Activation of kainate receptors on rat sensory neurons evokes action potential firing and may modulate transmitter release.
  21. (1993). Activation of nociceptive reflexes by peripheral kainate receptors.
  22. (2003). Activation of thalamic ventroposteriolateral neurons by phrenic nerve afferents in cats and rats.
  23. (1986). Activation of trigeminal brain-stem nociceptive neurons by dural artery stimulation.
  24. (2004). Acute drug treatment of migraine attack.
  25. (2004). Administration of MK-801 decreases c-Fos expression in the trigeminal sensory nuclear complex but increases it in the midbrain during experimental movement of rat molars.
  26. AE (1999a) Evaluation of agonists and antagonists acting at Group I metabotropic glutamate receptors in the thalamus in vivo.
  27. (2001). Agmon A
  28. (1997). Allelic association of juvenile absence epilepsy with a GluR5 kainate receptor gene (GRIK1) polymorphism.
  29. (1973). Alterations produced by cortisol in the spontaneous activity and responsiveness to sensory stimuli of single cells in the tuberal hypothalamus of the rat.
  30. (2005). Altered behavioral responses to noxious stimuli and fear in glutamate receptor 5 (GluR5)- or GluR6-deficient mice.
  31. (2001). Amino acids are still as exciting as ever.
  32. (1993). AMPA, KA and NMDA receptors are expressed in the rat DRG neurones.
  33. (1998). AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans.
  34. (2008). AMPA/Kainate receptor antagonist Tezampanel is effective in treating acute migraine.
  35. (1975). An analysis of the representation of the forelimb in the ventrobasal thalamic complex of the albino rat.
  36. (2006). An introduction to TRP channels.
  37. (1982). An ionophoretic study of the responses of rat caudal trigeminal nucleus neurones to non-noxious mechanical sensory stimuli.
  38. (2004). Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization.
  39. (1992). Anatomical and functional compartmentalization of the subparafascicular thalamic nucleus in the rat.
  40. (1994). Anatomical properties of brainstem trigeminal neurons that respond to electrical stimulation of dural blood vessels.
  41. (1997). Anatomy of the brainstem. In: Stereotaxy of the human brain, 2nd Edition,
  42. (2000). Anatomy of the central nervous sytem pathways related to head pain. In: The Headaches, 2nd Edition,
  43. (2006). Animal models of migraine: looking at the component parts of a complex disorder.
  44. (1999). Antagonism of the mGlu5 agonist 2-chloro-5-hydroxyphenylglycine by the novel selective mGlu5 antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) in the thalamus.
  45. (2007). Anti-convulsants and anti-depressants. Handb Exp Pharmacol:145-177.
  46. (2003). Anti-nociceptive effect induced by intrathecal injection of ATPA, an effect enhanced and prolonged by concanavalin A. Brain Res 959:275-279.
  47. (2006). Antiallodynic and antihyperalgesic effects of selective competitive GLUK5 (GluR5) ionotropic glutamate receptor antagonists in the capsaicin and carrageenan models in rats.
  48. (2006). Antiepileptic drugs in migraine prophylaxis. In: The Headaches, 3rd Edition
  49. (1995). Are the neurons in the dorsal root ganglion pseudounipolar? A comparison of the number of neurons and number of myelinated and unmyelinated fibres in the dorsal root.
  50. (2007). Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort.
  51. (1999). Astrocytes: glutamate producers for neurons.
  52. (2000). Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine.
  53. (1993). Autoradiographic characterisation and localisation of 5-HT1D compared to 5-HT1B binding sites in rat brain. Naunyn Schmiedebergs Arch Pharmacol 347:569-582. 274 Bruinvels
  54. (2001). Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [(3)H]GR 125743.
  55. (1989). Axonal tracing of autonomic nerve fibers to the superficial temporal artery in the rat.
  56. (2006). Bahra A
  57. (1965). Behavior and Reflexes of Chronic Thalamic Cats.
  58. Bigal ME (2005a) Migraine: epidemiology, impact, and risk factors for progression. Headache 45 Suppl 1:S3-S13.
  59. Bigal ME (2005b) The epidemiology of migraine.
  60. (1961). Biochemical investigations in headache:increase in hydroxyindoleaceticacid excreation during migraine attacks.
  61. (1991). Block of kainate receptor channels by Ca2+ in isolated spinal trigeminal neurons of rat.
  62. (1994). Blomqvist A
  63. (1995). Brain stem activation in spontaneous human migraine attacks.
  64. (2001). Brainstem activation specific to migraine headache.
  65. (1983). Bulbar raphe neurones with projections to the trigeminal nucleus caudalis and the lumbar cord in the rat: a fluorescence double-labelling study.
  66. (1993). Buonanno A
  67. (2008). Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype. Neurology 71:841-847. 282 Harris RM
  68. (2005). Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine.
  69. (2005). Calcium channels modulate nociceptive transmission in the trigeminal nucleus of the cat.
  70. (2007). Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons.
  71. (1996). Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study.
  72. (1981). Central dazzle. A thalamic syndrome?
  73. (1990). Central effect of the non-steroid anti-inflammatory agents, indomethacin, ibuprofen, and diclofenac, determined in C fibre-evoked activity in single neurones of the rat thalamus.
  74. (1993). Central hyperexcitability triggered by noxious inputs.
  75. (2003). Central projections of sensory innervation of the rat superficial temporal artery.
  76. (2004). Central projections of sensory innervation of the rat superior sagittal sinus.
  77. (2006). Central sensitization theory of migraine: clinical implications.
  78. (1991). Cerebral and extracranial circulatory disturbances in migraine: pathophysiological implications.
  79. (1995). Cerebrospinal fluid analyses in migraine patients and controls.
  80. (2004). Cerebrospinal fluid glutamate levels in chronic migraine.
  81. (1988). Cerebrovascular application of bradykinin excites central sensory neurons.
  82. (1992). Cervicothalamic tract terminals are enriched in glutamate-like immunoreactivity: an electron microscopic double-labeling study in the cat.
  83. (2000). CGRP involvement in migraines. In: The Headaches, 2nd Edition,
  84. (2002). CGRP may play a causative role in migraine.
  85. (1988). Changes in hypothalamic temperature modulate the neuronal response of the ventral thalamus to skin warming in rats.
  86. (2004). Characterisation of the effects of ATPA, a GLU(K5) kainate receptor agonist, on GABAergic synaptic transmission in the CA1 region of rat hippocampal slices.
  87. (2004). Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist.
  88. (1993). Characteristics of headache at menopause: a clinico-epidemiologic study.
  89. (1990). Characterization of descending inhibition and facilitation from the nuclei reticularis gigantocellularis and gigantocellularis pars alpha in the rat.
  90. (1998). Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons.
  91. (1993). Chromosomal localization of gene for human glutamate receptor subunit-7. Somat Cell Mol Genet
  92. Chronicle EP (2008) Anticonvulsants in migraine prophylaxis: a Cochrane review.
  93. (1990). Cloning of a novel glutamate receptor subunit, GluR5: expression in the nervous system during development.
  94. (2002). Closure of the Venus flytrap module of mGlu8 receptor and the activation process: Insights from mutations converting antagonists into agonists.
  95. (2001). Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats.
  96. (1987). Collateral projections from trigeminal sensory nuclei to ventrobasal thalamus and cerebellar cortex in rats.
  97. (2002). Common and selective molecular determinants involved in metabotopic glutamate receptor agonist activity.
  98. (1988). Comparative effects of stimulation of the trigeminal ganglion and the superior sagittal sinus on cerebral blood flow and evoked potentials in the cat.
  99. (2001). Contributions of the medullary raphe and ventromedial reticular region to pain modulation and other homeostatic functions.
  100. (1995). Convergence of afferents from superior sagittal sinus and tooth pulp on cells in the thalamus of the cat.
  101. (2003). Convergence of cervical and trigeminal sensory afferents. Curr Pain Headache Rep 7:377-383.
  102. (2002). Correlation of the expression of kainate receptor subtypes to responses evoked in cultured cortical and spinal cord neurones.
  103. (2008). Cortico-NRM influences on trigeminal neuronal sensation.
  104. (1992). Corticothalamic activation modulates thalamic firing through glutamate "metabotropic" receptors.
  105. (2000). Cranial nerves and cranial nerve nuclei.
  106. (1991). Craniovascular application of capsaicin activates nociceptive thalamic neurones in the cat.
  107. (2005). Crystal structures of the GluR5 and GluR6 ligand binding cores: molecular mechanisms underlying kainate receptor selectivity.
  108. (2000). D-serine is an endogenous ligand for the glycine site of the Nmethyl-D-aspartate receptor.
  109. (2005). D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices.
  110. (1998). Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia.
  111. (2001). Deconstructing migraine headache into peripheral and central sensitization.
  112. (2003). Decreased habituation of the R2 component of the blink reflex in migraine patients.
  113. (2004). Defeating migraine pain with triptans: a race against the development of cutaneous allodynia.
  114. (1995). Dependence of sensorimotor cortex neuron activity on noradrenergic and serotoninergic transmission in unspecific thalamic nuclei.
  115. (1997). Desensitization of kainate receptors by kainate, glutamate and diastereomers of 4-methylglutamate.
  116. (1998). Detailed mapping of serotonin 5-HT1B and 5-HT1D receptor messenger RNA and ligand binding sites in guinea-pig brain and trigeminal ganglion: clues for function.
  117. (1993). Determinants of Ca2+ permeability in both TM1 and TM2 of high affinity kainate receptor channels: diversity by RNA editing.
  118. (1984). Diencephalic connections of the raphe nuclei of the rat brainstem: an anatomical study with reference to the somatosensory system.
  119. (1997). Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs.
  120. (1996). Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.
  121. (1992). Differential roles of NMDA and nonNMDA receptor activation in induction and maintenance of thermal hyperalgesia in rats with painful peripheral mononeuropathy.
  122. (2000). Differential sensitivity of recombinant GABA(A) receptors expressed in Xenopus oocytes to modulation by topiramate.
  123. (1978). Differentiation of dopaminergic and noradrenergic neurons in rat spinal cord.
  124. (1990). Direct catecholaminergic innervation of primate spinothalamic tract neurons.
  125. (2001). Direct presynaptic regulation of GABA/glycine release by kainate receptors in the dorsal horn: an ionotropic mechanism.
  126. (2005). Discovering statistics using SPSS, 2nd Edition. London: Sage Publigations.
  127. (1996). Distribution of trigeminothalamic and spinothalamic-tract neurons showing substance P receptor-like immunoreactivity in the rat.
  128. (1979). Distribution of trigeminothalamic projection cells in cat and monkey.
  129. (2006). Distribution of vesicular glutamate transporters 1 and 2 in the rat spinal cord, with a note on the spinocervical tract.
  130. (1991). Distributions of spinothalamic, spinohypothalamic, and spinotelencephalic fibers revealed by anterograde transport of PHA-L in rats.
  131. (1998). Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological, and therapeutic data.
  132. (1997). Dopamine and migraine.
  133. (1979). Dual alterations of thalamic nociceptive activity by stimulation of the periaqueductal gray matter.
  134. (1940). dural headache and innervation of the dura matter.
  135. (2003). Early intervention with almotriptan improves sustained pain-free response in acute migraine.
  136. Ebner FF (1994a) The role of GABA-mediated inhibition in the rat ventral posterior medial thalamus. I. Assessment of receptive field changes following thalamic reticular nucleus lesions.
  137. Ebner FF (1994b) The role of GABA-mediated inhibition in the rat ventral posterior medial thalamus. II. Differential effects of GABAA and GABAB receptor antagonists on responses of VPM neurons.
  138. Edvinsson L (2005a) Presence and function of the calcitonin gene-related peptide receptor on rat pial arteries investigated in vitro and in vivo.
  139. (2005). Effect of hypotension and carbon dioxide changes in an improved genuine closed cranial window rat model.
  140. (1960). Effect of serotonin in migraine patients.
  141. (2003). Eikermann A
  142. (1976). EMG-biofeedback reduction of tension headache: a cognitive skills-training approach.
  143. (1980). Encoding of noxious heat messages in neurons of the ventrobasal thalamic complex of the rat.
  144. (1996). Endogenous monoamines inhibit glutamate transmission in the spinal trigeminal nucleus of the guinea-pig.
  145. (1993). Enzymes involved in glutamatergic and GABAergic neurotransmission.
  146. (1991). Epidemiology of headache in a general population--a prevalence study.
  147. (2005). Epidemiology of migraine. In: Atlas of migraine and other headaches, 2nd Edition (Silberstein SD,
  148. (2006). Epidemiology of migraine. In: The Headaches, 3rd Edition
  149. (2007). Ethanol causes neurogenic vasodilation by TRPV1 activation and CGRP release in the trigeminovascular system of the guinea pig.
  150. (2002). Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.
  151. (1999). Evidence for an inflammation-induced change in the local glutamatergic regulation of postganglionic sympathetic efferents.
  152. (2001). Evidence for postjunctional serotonin (5-HT1) receptors in the trigeminocervical complex.
  153. (1979). Evidence that an excitatory connection between the periaqueductal gray and nucleus raphe magnus mediates stimulation produced analgesia.
  154. (1996). Evidence that excitatory amino acids mediate afferent input to the primate somatosensory thalamus.
  155. (1998). Evidence that functional glutamate receptors are not expressed on rat or human cerebromicrovascular endothelial cells.
  156. (1994). Evolution of a novel series of [(N,N-dimethylamino)propyl]- and piperazinylbenzanilides as the first selective 5-HT1D antagonists.
  157. (1979). Excitatory amino acid receptors and synaptic excitation in the mammalian central nervous system.
  158. (1981). Excitatory amino acid transmitters.
  159. (1996). Excitatory amino release within spinal trigeminal nucleus after mustard oil injection into the temporomandibular joint region of the rat.
  160. (1940). Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Archives
  161. (2001). Exploring the Thalamus. San Diego:
  162. (1994). Extent of RNA editing of glutamate receptor subunit GluR5 in different brain regions of the rat.
  163. (1986). Extent of the ipsilateral representation in the ventral posterior medial nucleus of the monkey thalamus.
  164. (2001). Extracellular glutamate, aspartate and arginine increase in the ventral posterolateral thalamic nucleus during nociceptive stimulation.
  165. (1996). Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4.
  166. (1974). Fiber projections from trigeminal nucleus caudalis in primate (squirrel monkey and baboon).
  167. (2002). From CSD to headache: a long and winding road.
  168. (1981). Functional changes in ventrobasal thalamic neurones responsive to noxious and non-noxious cutaneous stimuli after chloralose treatment: new evidence for the presence of pre-existing "silent connections" in the adult nervous system?
  169. (2001). Functional diversity and developmental changes in rat neuronal kainate receptors.
  170. (2002). Functional expression of AMPA receptors on central terminals of rat dorsal root ganglion neurons and presynaptic inhibition of glutamate release.
  171. (1981). Functional properties of neurons in cat trigeminal subnucleus caudalis (medullary dorsal horn). I. Responses to oral-facial noxious and nonnoxious stimuli and projections to thalamus and subnucleus oralis.
  172. (1980). GABA neurons are the major cell type of the nucleus reticularis thalami.
  173. (2003). GABA receptors modulate trigeminovascular nociceptive neurotransmission in the VPM thalamic nucleus of the rat. Cephalalgia 23:728.
  174. (1990). GABA(B)-related activity involved in synaptic processing of somatosensory information in S1 cortex of the anaesthetized cat.
  175. (1993). GABAA-receptor immunoreactivity in the rat dorsal thalamus: an ultrastructural investigation.
  176. (1997). GABAergic neurons in mammalian thalamus: a marker of thalamic complexity?
  177. (1989). Gamma-aminobutyric acid and afferent inhibition in the cat and rat ventrobasal thalamus.
  178. (2006). Genetic and pharmacological studies of GluR5 modulation of inhibitory synaptic transmission in the anterior cingulate cortex of adult mice.
  179. (1994). Genetic and physical mapping of the GLUR5 glutamate receptor gene on human chromosome 21. Hum Genet 94:565-570.
  180. (2006). Genetic biomarkers for migraine.
  181. (2003). Genetic loading in familial migraine with aura.
  182. (1997). Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease.
  183. (2004). GluR5 Kainate Receptors and Topiramate: A New Site of Action for Antiepileptic Drugs? Epilepsy Curr 4:17.
  184. (2003). GluR5 kainate receptors, seizures, and the amygdala.
  185. (2009). Glutamate and capsaicin effects on trigeminal nociception I: Activation and peripheral sensitization of deep craniofacial nociceptive afferents.
  186. (2002). Glutamate and the presynaptic control of spinal sensory transmission.
  187. (1988). Glutamate neurotoxicity and diseases of the nervous system.
  188. (1990). Glutamate receptor channels in rat DRG neurons: activation by kainate and quisqualate and blockade of desensitization by Con A.
  189. (2002). Glutamate receptor functions in sensory relay in the thalamus.
  190. (1997). Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons.
  191. (2001). Glutamate receptors and nociception: implications for the drug treatment of pain.
  192. (2006). Glutamate receptors and pain.
  193. (1998). Glutamate receptors in the mammalian central nervous system.
  194. (1998). Glutamate receptors on postganglionic sympathetic axons.
  195. (1991). Glutamate-immunoreactivity in the trigeminal and dorsal root ganglia, and intraspinal neurons and fibres in the dorsal horn of the rat.
  196. (2000). Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow.
  197. (1991). Glutamine synthetase in oligodendrocytes and astrocytes: new biochemical and immunocytochemical evidence.
  198. (2004). Glyceryl trinitrate triggers premonitory symptoms in migraineurs.
  199. Goadsby PJ (2002b) The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels.
  200. Goadsby PJ (2002c) Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels.
  201. Goadsby PJ (2003a) The trigeminocervical complex and migraine: current concepts and synthesis. Curr Pain Headache Rep 7:371-376.
  202. Goadsby PJ (2003a) Voltage-dependent calcium channels are involved in neurogenic dural vasodilatation via a presynaptic transmitter release mechanism.
  203. Goadsby PJ (2003b) Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater.
  204. Goadsby PJ (2003b) Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation.
  205. Goadsby PJ (2004a) Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat.
  206. Goadsby PJ (2004b) Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception.
  207. Goadsby PJ (2004b) GABAA receptor modulation of trigeminovascular nociceptive neurotransmission by midazolam is antagonized by flumazenil.
  208. Goadsby PJ (2005a) A positron emission tomographic study in spontaneous migraine.
  209. Goadsby PJ (2005a) Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura.
  210. Goadsby PJ (2005b) A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate.
  211. Goadsby PJ (2005b) Topiramate inhibits trigeminovascular activation: an intravital microscopy study.
  212. Goadsby PJ (2005c) The role of dopamine in a model of trigeminovascular nociception.
  213. (2007). GRIK4 and the kainate receptor.
  214. (1994). GYKI 52466 inhibits AMPA/kainate and peripheral mechanical sensory activity.
  215. Hargreaves RJ (1997b) The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation.
  216. (1948). Headache and Other Head Pain, 1st Edition.
  217. (1998). Headache as a major public health problem: current status.
  218. (1993). Headache caused by a single lesion of multiple sclerosis in the periaqueductal gray area.
  219. (2004). Headache Classification Committee of the International Headache Society
  220. (1987). Headache may arise from perturbation of brain.
  221. (1998). Headache secondary to deep brain implantation.
  222. (1994). Histological and ultrastructural localization of the kainate receptor subunits, KA2 and GluR6/7, in the rat nervous system using selective antipeptide antibodies.
  223. Huettner JE (2001a) Presynaptic kainate receptors regulate spinal sensory transmission.
  224. (1994). Human GluR6 kainate receptor (GRIK2): molecular cloning, expression, polymorphism, and chromosomal assignment.
  225. (2007). Human heart glutamate receptors - implications for toxicology, food safety, and drug discovery.
  226. (1989). Hyperperfusion of cerebral cortex, thalamus and basal ganglia during spontaneously occurring migraine headaches.
  227. (2004). Hypothalamic activation after stimulation of the superior sagittal sinus in the cat: a Fos study.
  228. (2007). Hypothalamic activation in spontaneous migraine attacks.
  229. (2001). Hypothalamic involvement in chronic migraine.
  230. (1999). Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients.
  231. (1995). Increase of meningeal blood flow after electrical stimulation of rat dura mater encephali: mediation by calcitonin generelated peptide.
  232. (1997). Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study.
  233. (1997). Influence of AMPA/kainate receptors on extracellular 5-hydroxytryptamine in rat midbrain raphe and forebrain.
  234. (1984). Inhibition of thalamic ventrobasal complex neurons by glutamate infusion into the thalamic reticular nucleus in rats.
  235. (2000). Inhibition suppresses transmission of tonic vibrissa-evoked activity in the rat ventrobasal thalamus.
  236. (2004). Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat.
  237. (1977). Innervation of intracranial structures: a reappraisal. In: Physiological aspects of Clinical Neurology (Rose FC,
  238. (1989). Interaction of 6-cyano-7-nitroquinoxaline-2,3-dione with the N-methyl-D-aspartate receptor-associated glycine binding site.
  239. (1994). International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev
  240. (1996). Intracerebral arteries and gadolinium enhancement in migraine without aura.
  241. (1978). Intratrigeminal and thalamic projections of nucleus caudalis in the squirrel monkey (Saimiri sciureus): a degeneration and autoradiographic study.
  242. (1993). Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 33:541-544. 285 Kaube
  243. (1989). Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 38:17-24. 284
  244. (2002). Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model.
  245. (2005). Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl)
  246. (2001). Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? Ann Neurol 49:7-13. 278 Edvinsson L, Uddman R
  247. (2006). It is AMPA receptor, not kainate receptor, that contributes to the NBQX-induced antinociception in the spinal cord of rats.
  248. (1997). Kainate microinjection into the dorsal raphe nucleus induces 5-HT release in the amygdala and periaqueductal gray.
  249. (2003). Kainate receptor (GluR5)-mediated disinhibition of responses in rat ventrobasal thalamus allows a novel sensory processing mechanism.
  250. (1994). Kainate receptor gene expression in the developing rat brain.
  251. (2002). Kainate receptor subunits underlying presynaptic regulation of transmitter release in the dorsal horn.
  252. (2002). Kainate receptor-dependent presynaptic modulation and plasticity.
  253. (2000). Kainate receptor-mediated presynaptic inhibition at the mouse hippocampal mossy fibre synapse.
  254. (2007). Kainate receptors and pain: from dorsal root ganglion to the anterior cingulate cortex.
  255. (2003). Kainate receptors and synaptic transmission.
  256. (1999). Kainate receptors are involved in synaptic plasticity.
  257. (2007). Kainate receptors are primarily postsynaptic to SP-containing axon terminals in the trigeminal dorsal horn. Brain Res.
  258. (2001). Kainate receptors at corticothalamic synapses do not contribute to synaptic responses. Thalamus Related Systems 1:187–196.
  259. (1998). Kainate receptors exhibit differential sensitivities to (S)-5-iodowillardiine. Mol Pharmacol 53:942-949.
  260. (2006). Kainate receptors.
  261. (1990). Karle A
  262. (1996). Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate.
  263. (2001). Lanepitant, an NK-1 antagonist, in migraine prevention.
  264. (1997). Lateralization and functional organization of the locus coeruleus projection to the trigeminal somatosensory pathway in rat.
  265. Lesko LM (2004b) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.
  266. (1993). Light and electron microscopic localization of calcitonin gene-related peptide immunoreactivity in lamina II of the feline trigeminal pars caudalis/medullary dorsal horn: a qualitative study.
  267. (1995). Localization and activation of glutamate receptors in unmyelinated axons of rat glabrous skin.
  268. (1991). Localization of 3H-dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine.
  269. (2000). Localization of ionotropic glutamate receptors in peripheral axons of human skin.
  270. (2005). Localization of kainate receptor subunit GluR5-immunoreactive cells in the rat hypothalamus.
  271. (1994). Localization of neuronal and glial glutamate transporters.
  272. (1986). Localization of responses in the somatosensory thalamus of the rat.
  273. (1983). Low dose of morphine microinjected in the ventral periaqueductal gray matter of the rat depresses responses of nociceptive ventrobasal thalamic neurons.
  274. (1987). Low extracellular magnesium induces epileptiform activity and spreading depression in rat hippocampal slices.
  275. (2004). LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine.
  276. (2009). MaassenVanDenBrink A
  277. (2002). Main subunits of ionotropic glutamate receptors are expressed in isolated rat brain microvessels.
  278. (1997). Mandelzys A
  279. Meador-Woodruff JH (2000a) Nucleus-specific expression of ionotropic glutamate receptor subunit mRNAs and binding sites in primate thalamus.
  280. Meador-Woodruff JH (2000b) Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia.
  281. (2000). Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan.
  282. (2002). Mechanisms of action of the 5-HT1B/1D receptor agonists.
  283. (2001). Mechanisms of migraine aura revealed by functional MRI in human visual cortex.
  284. (2001). Mechanisms of spreading depression and hypoxic spreading depression-like depolarization.
  285. (2000). Menstrual cycle and headache in a population sample of migraineurs.
  286. (1981). Microelectrode methods of intracellular recording and iontophoresis.
  287. (1985). Microiontophoresis and Pressure Injection.
  288. (1964). Microiontophoresis. In:
  289. (1997). Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat.
  290. (1982). Microiontophoretically applied 5-HT reduces responses to noxious stimulation in the thalamus.
  291. (1975). Migraine and reporoductive hormones throughout the menstrual cycle.
  292. (2004). Migraine aura: new information on underlying mechanisms.
  293. (2001). Migraine diagnosis and treatment. In: Wolff's headache and other head pain,
  294. (1999). Migraine in the menopause.
  295. (2002). Migraine in the United States: epidemiology and patterns of health care use.
  296. (1998). Migraine in twins raised together and apart.
  297. (1992). Migraine with aura and migraine without aura: an epidemiological study.
  298. (2002). Migraine--current understanding and treatment.
  299. (2001). Migraine, aura, and cortical spreading depression: why are we still talking about it? Ann Neurol 49:4-6. 280 Goadsby PJ
  300. (1991). Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of young adults.
  301. (2007). Migraine: a complex genetic disorder.
  302. (2007). Migraine: gene mutations and functional consequences.
  303. (1992). Migraine: theories of pathogenesis.
  304. (1988). MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys.
  305. (2004). Modulation of excitatory synaptic transmission in the spinal substantia gelatinosa of mice deficient in the kainate receptor
  306. (2006). Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat.
  307. (1998). Modulation of sensory inhibition in the ventrobasal thalamus via activation of group II metabotropic glutamate receptors by 2R,4R-aminopyrrolidine-2,4-dicarboxylate.
  308. (1995). Modulation of sensory neurone excitatory and inhibitory responses in the ventrobasal thalamus by activation of metabotropic excitatory amino acid receptors.
  309. (1989). Modulatory effects of serotonin on excitatory amino acid responses and sensory synaptic transmission in the ventrobasal thalamus.
  310. (1998). Molecular and immunochemical characterization of the ionotropic glutamate receptors in the rat heart.
  311. (2001). Molecular physiology of kainate receptors.
  312. (2005). Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine.
  313. (1993). Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms.
  314. (1987). Nerve fibres and their terminals of the dura mater encephali of the rat. Anat Embryol (Berl)
  315. (1991). Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine.
  316. (1986). Neuroanatomy for Medical Students, 3rd Edition.
  317. (2006). Neurochemistry of trigeminal activation in an animal model of migraine.
  318. (1993). Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks.
  319. (1990). Neuroexcitatory plasma amino acids are elevated in migraine.
  320. (2005). Neurogenic inflammation and migraine: implications for the therapeutics.
  321. (2006). Neuroimaging of migraine.
  322. (1977). Neuronal and behavioural responses in rats during noxious stimulation of the tail.
  323. (2003). Neuronal glutamate transporter EAAT4 is expressed in astrocytes.
  324. (2000). Neuronal plasticity: increasing the gain in pain.
  325. (1980). Neurones responding to noxious stimulation in VB complex and caudal adjacent regions in the thalamus of the rat.
  326. (1983). Neurons in ventrobasal region of cat thalamus selectively responsive to noxious mechanical stimulation.
  327. (1983). Neuropeptide Y: cerebrovascular innervation and vasomotor effects in the cat.
  328. (1998). Neuropeptides in headache.
  329. (1994). Neuropeptides in migraine and cluster headache.
  330. (1995). Neuropeptides in the cerebral circulation: relevance to headache.
  331. (1998). Neuropeptises in Headache.
  332. (1991). Neurotransmitters in nociceptive modulatory circuits.
  333. (1993). Neurovascular and molecular mechanisms in migraine headaches.
  334. (2006). New and future migraine therapy.
  335. (1996). New developments in the molecular pharmacology of alphaamino-3-hydroxy-5-methyl-4-isoxazole propionate and kainate receptors.
  336. (1994). Nitroglycerin-induced headache is not dependent on histamine release: support for a direct nociceptive action of nitric oxide.
  337. (1992). NMDA-receptor blockers but not NBQX, an AMPA-receptor antagonist, inhibit spreading depression in the rat brain.
  338. (2004). No effect of eletriptan administration during the aura phase of migraine.
  339. (2007). Nociceptors--noxious stimulus detectors.
  340. (1999). Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis.
  341. (1960). Observations on 500 cases of migraine and allied vascular headache.
  342. (2000). Observations on the relationship between the extracellular changes of taurine and glutamate during cortical spreading depression, 298 during ischemia, and within the area surrounding a thrombotic infarct.
  343. (2007). Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment.
  344. (1950). On the anatomical and functional organization of the spinal trigeminal nucleus.
  345. (1932). Operative treatment of migraine and observations on the mechanisms of vascular pain.
  346. (2005). Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception.
  347. (1986). Origin and distribution of cerebral vascular innervation from superior cervical, trigeminal and spinal ganglia investigated with retrograde and anterograde WGA-HRP tracing in the rat.
  348. (2002). P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine?
  349. (2004). Palotie A
  350. (1994). Parabrachial area and nucleus raphe magnus-induced modulation of nociceptive and nonnociceptive trigeminal subnucleus caudalis neurons activated by cutaneous or deep inputs.
  351. (1994). Pathophysiology of the migraine aura. The spreading depression theory.
  352. (1941). Patterns of cerebral integration indicated by the scotomas of migraine.
  353. (2005). Patterns of fos expression in the rostral medulla and caudal pons evoked by noxious 286 craniovascular stimulation and periaqueductal gray stimulation in the cat.
  354. (1991). Peptidergic and serotoninergic innervation of the rat dura mater.
  355. (1999). Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy.
  356. (2006). Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.
  357. (2000). Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.
  358. (1998). Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache.
  359. (1967). Plasma serotonin in migraine and stress.
  360. (1995). Platelet and plasma levels of glutamate and glutamine in migraine with and without aura.
  361. (1991). Platelet glycine, glutamate and aspartate in primary headache.
  362. (1980). Plaznik A
  363. (1999). Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia
  364. (1997). Possible mechanism of c-fos expression in trigeminal nucleus caudalis following cortical spreading depression.
  365. (1997). Prader-Willi syndrome and the hypothalamus.
  366. (2006). Premonitory and resolution symptoms in migraine: a prospective study in 100 unselected patients.
  367. (2003). Premonitory symptoms in migraine: an electronic diary study.
  368. (2005). Presynaptic calcium and control of vesicle fusion.
  369. (2001). Presynaptic kainate receptors in primary afferents to the superficial laminae of the rat spinal cord.
  370. (2001). Presynaptic kainate receptors in the hippocampus: slowly emerging from obscurity.
  371. (2004). Presynaptic NMDA receptors modulate glutamate release from primary sensory neurons in rat spinal cord dorsal horn.
  372. (2001). Prevalence and burden of migraine in the United States: data from the American Migraine Study II.
  373. (1995). Prevalence and sex-ratio of the subtypes of migraine.
  374. (2000). Primary afferent synaptic responses recorded from trigeminal caudal neurons in a mandibular nerve-brainstem preparation of neonatal rats.
  375. (2003). Primary afferent terminals that express presynaptic NR1 in rats are mainly from myelinated, mechanosensitive fibers.
  376. (1983). Principal Differences in the Organization of the Thalamic Face Representation in Rodents and Felids. In:
  377. (2005). Prodromes and predictors of migraine attack.
  378. (1983). Projections from brain stem nuclei to the spinal trigeminal nucleus in the cat.
  379. (1988). Properties of feline thalamic neurons activated by stimulation of the middle meningeal artery and sagittal sinus.
  380. (2005). Properties of neurons in the trigeminal nucleus caudalis responding to noxious dural and facial stimulation.
  381. (2005). Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine?
  382. (2004). Protective effect of ifenprodil against spreading depression in the mouse entorhinal cortex.
  383. (1991). Quantitative autoradiographic analysis of excitatory amino acid receptors in the cat spinal cord.
  384. (1984). Quantitative autoradiographic distribution of L[3H]glutamate-binding sites in rat central nervous system.
  385. (2008). Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.
  386. (1993). Raphe magnus stimulation-induced antinociception in the cat is associated with release of amino acids as well as serotonin in the lumbar dorsal horn.
  387. (2007). Recent advances in understanding migraine mechanisms, molecules and therapeutics.
  388. (1987). Receptive-field properties of rat ventral posterior medial neurons before and after selective kainic acid lesions of the trigeminal brain stem complex.
  389. (1973). Receptor categories represented in spinal trigeminal nucleus caudalis.
  390. (2001). Receptor systems mediating c-fos expression within trigeminal nucleus caudalis in animal models of migraine.
  391. (1997). Recordings from brain stem neurons responding to chemical stimulation of the subarachnoid space.
  392. (2002). Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells.
  393. (2007). Reduced expression of calcitonon gene related peptide in mice with familial hemiplegic migraine (FHM) 1 mutation.
  394. (1971). Referral of pain from dural stimulation in man.
  395. (1995). Regional brain glutamate transport in rats at normal and raised concentrations of circulating glutamate.
  396. (1998). Regional cerebral blood flow and oxygen metabolism during migraine with and without aura.
  397. (2005). Regional expression of 5-HT1B receptor mRNA in the human brain.
  398. (2008). Release of glutamate and CGRP from trigeminal ganglion neurons: Role of calcium channels and 5-HT1 receptor signaling.
  399. (1988). Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system.
  400. (1982). Resolution of migraine attacks: sleep and the recovery phase.
  401. (1986). Response of brainstem trigeminal neurons to electrical stimulation of the dura.
  402. (1957). Response properties of neurons of cat's somatic sensory cortex to peripheral stimuli.
  403. (1990). Response properties of nociceptive and non-nociceptive neurons in the rat's trigeminal subnucleus caudalis (medullary dorsal horn) related to cutaneous and deep craniofacial afferent stimulation and modulation by diffuse noxious inhibitory controls.
  404. (1999). Response properties of trigeminal brain stem neurons with input from dura mater encephali in the rat.
  405. (1994). Responses of cerebral arterioles to kainate. Stroke 25:2080-2083; discussion
  406. (1993). Responses of neurons in and near the thalamic ventrobasal complex of the rat to stimulation of uterus, cervix, vagina, colon, and skin.
  407. (1983). Reticularis thalami afferents to the ventrobasal complex of the rat thalamus: an electron microscope study.
  408. (2006). Rodriguez-Moreno A
  409. (2002). Role of carbon monoxide in glutamate receptorinduced dilation of newborn pig pial arterioles. Am J Physiol Heart Circ Physiol 282:H2371-2376. 296 Rodriguez-Moreno A, Sihra TS
  410. (2002). Role of kainate receptors in nociception.
  411. (2005). Role of KATP channels in the regulation of rat dura and pia artery diameter.
  412. (2005). Role of spinal cord glutamate transporter during normal sensory transmission and pathological pain states. Mol Pain 1:30.
  413. (1997). Role of the suprachiasmatic nucleus in the pathogenesis of migraine attacks.
  414. (2003). Roles and rules of kainate receptors in synaptic transmission.
  415. (2006). Rustioni A
  416. (1994). Selective 5-HT1D alpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development.
  417. (1995). Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons.
  418. (2003). Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons.
  419. (1994). Selective block of recombinant glur6 receptors by NS-102, a novel non-NMDA receptor antagonist.
  420. (1993). Selective loss of neurons from the thalamic reticular nucleus following severe human head injury.
  421. (1996). Sensitization of meningeal sensory neurons and the origin of headaches.
  422. (2000). Serotonergic Raphe magnus cells that respond to noxious tail heat are not ON or OFF cells.
  423. (1990). Serotonin and migraine.
  424. (1994). Serotonin immunoreactivity is contained in one physiological cell class in the rat rostral ventromedial medulla.
  425. (2006). Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target?
  426. (1984). Serotonin-containing projections to the thalamus in the rat revealed by a horseradish peroxidase and peroxidase antiperoxidase double-staining technique.
  427. (1987). Serrano A
  428. (1988). Single thalamic dopaminergic neurons project to both the neocortex and spinal cord.
  429. (2005). Sodium channel mutations in epilepsy and other neurological disorders.
  430. (1968). Somatic afferent input to posterior thalamic neurones and their axon projection to the cerebral cortex in the cat.
  431. (2002). Somatotopic activation in the human trigeminal pain pathway.
  432. (1985). Somatotopic distribution of trigeminal nociceptive neurons in ventrobasal complex of cat thalamus.
  433. (1973). Somatotopic organization of vibrissal responses in the ventro-basal complex of the rat thalamus.
  434. (2005). Spatiotemporal gating of sensory inputs in thalamus during quiescent and activated states.
  435. (1983). Spinal and trigeminal mechanisms of nociception.
  436. (2005). Spinal glutamate uptake is critical for maintaining normal sensory transmission in rat spinal cord.
  437. (1979). Spinal serotonin terminal system mediates antinociception.
  438. (1993). Spreading depression induces c-fos-like immunoreactivity and NGF mRNA in the rat cerebral cortex.
  439. (1944). Spreading depression of activity in cerebral cortex.
  440. (1990). Stimulation of cranial vessels excites nociceptive neurones in several thalamic nuclei of the cat.
  441. (1990). Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides.
  442. (1991). Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat.
  443. (1976). Studies on the neuropharmacological activity of bicuculline and related compounds.
  444. (2005). Subcellular localization and trafficking of kainate receptors.
  445. (1994). Subcutaneous sumatriptan during the migraine aura.
  446. (1983). Substance P: localization, concentration and release in cerebral arteries, choroid plexus and dura mater.
  447. (2004). Subunit composition and alternative splicing regulate membrane delivery of kainate receptors.
  448. (2003). Subunit-dependent modulation of kainate receptors by extracellular protons and polyamines.
  449. (1997). Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat--intravital microscope studies.
  450. (2003). SYM 2081, an agonist that desensitizes kainate receptors, attenuates capsaicin and inflammatory hyperalgesia.
  451. (1989). Sympathetic innervation of the supratentorial dura mater of the rat.
  452. (2001). Synaptic activation of a presynaptic kainate receptor facilitates AMPA receptor- 287 mediated synaptic transmission at hippocampal mossy fibre synapses.
  453. (2005). Synaptic input of rat spinal lamina I projection and unidentified neurones in vitro.
  454. (2005). Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
  455. (1989). Thalamic mechanism of pain: shell theory of thalamic nociception.
  456. (1961). Thalamic projections of spinothalamic pathways in monkey.
  457. (1990). Thalamus. In: The Human Nervous System (Paxinos
  458. (2003). Thalamus. In: The human nervous system., 2nd Edition (Paxinos G,
  459. (1983). The activity of neurons in the rostral medulla of the rat during withdrawal from noxious heat.
  460. (2001). The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs.
  461. (1979). The cells of origin of the primate spinothalamic tract.
  462. (1982). The cells of origin of the trigeminothalamic, trigeminospinal and trigeminocerebellar projections in the cat.
  463. (2004). The contribution of the principal and spinal trigeminal nuclei to the receptive field properties of thalamic VPM neurons in the rat.
  464. (2000). The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine.
  465. (1993). The differential expression of 16 NMDA and non-NMDA receptor subunits in the rat spinal cord and in periaqueductal gray.
  466. (1982). The distribution of [3H]kainic acid binding sites in rat CNS as determined by autoradiography.
  467. (1997). The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study.
  468. (2001). The effect of adrenergic compounds on neurogenic dural vasodilatation.
  469. (1992). The effect of glutamate receptor blockade on anoxic depolarization and cortical spreading depression.
  470. (1981). The effect of infused prostacyclin in migraine and cluster headache.
  471. (2003). The effect of prodrome on cognitive efficiency. Headache 43:518.
  472. (2001). The expression of vesicular glutamate transporters defines two classes of excitatory synapse.
  473. (2003). The expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in neurochemically defined axonal populations in the rat spinal cord with emphasis on the dorsal horn.
  474. (1994). The genes encoding the glutamate receptor subunits KA1 and KA2 (GRIK4 and GRIK5) are located on separate chromosomes in human, mouse, and rat.
  475. (2000). The global burden of disease study: implications for neurology.
  476. (2006). The glutamate story.
  477. (1988). The human central nervous system- A synopsis and atlas.
  478. (1990). The hypothalamus. In: The human nervous system (Paxinos
  479. (2002). The identification of vesicular glutamate transporter 3 suggests novel modes of signaling by glutamate.
  480. (1991). The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states.
  481. (1999). The induction of pain: an integrative review.
  482. (1999). The kainate receptor antagonist 2S,4R-4-methylglutamate attenuates mechanical allodynia and thermal hyperalgesia in a rat model of nerve injury.
  483. (2003). The link between glutamate and migraine.
  484. (1984). The meningeal representation in the trigeminal ganglion--an experimental study in the cat.
  485. (1998). The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis.
  486. (2001). The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity within the trigeminocervical complex following superior sagittal sinus stimulation in the cat.
  487. (2007). The novel p.L1649Q mutation in the SCN1A epilepsy gene is associated with familial hemiplegic migraine: genetic and functional studies. Mutation in brief #957.
  488. (1998). The number of glutamate transporter subtype molecules at glutamatergic synapses: chemical and stereological quantification in young adult rat brain.
  489. (1994). The pathophysiology of chronic pain--increased sensitivity to low threshold A beta-fibre inputs.
  490. (2001). The periaqueductal grey matter modulates trigeminovascular input: a role in migraine?
  491. (2000). The pharmacology of headache.
  492. (1999). The prevalence and characteristics of migraine in a population-based cohort: the GEM study.
  493. (2003). The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity.
  494. (2006). The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients.
  495. (1986). The primary afferent depolarizing action of kainate in the rat.
  496. (2005). The primate thalamus is a key target for brain dopamine.
  497. (1997). The rat brain in stereotaxic coordinates. San Diego:
  498. (1954). The representation of cutaneous sense in the thalamus of the cat and monkey.
  499. (1967). The responses of thalamic neurons to iontophoretically applied monoamines.
  500. (2007). The role of glutamate and its receptors in migraine.
  501. (2003). The role of nitric oxide in vascular headache.
  502. (1999). The role of non-N-methyl-D-aspartate ionotropic glutamate receptors in the spinal transmission of nociception in normal animals and animals with carrageenan inflammation.
  503. (1992). The spinal cord processing of input from the superior sagittal sinus: pathway and modulation by ergot alkaloids.
  504. (2006). The thalamus, 2nd Edition. Cambridge:
  505. (1992). The time course of glutamate in the synaptic cleft.
  506. (2000). The trigeminal nerve. Part I: An over-view.
  507. (1993). The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats.
  508. (2007). The triggers or precipitants of the acute migraine attack.
  509. (1974). To spritz or not to spritz: the doubtful value of aimless iontophoresis.
  510. (2000). Topiramate as an inhibitor of carbonic anhydrase isoenzymes.
  511. (2006). Topiramate in migraine prophylaxis: data from a pooled analysis and open-label extension study.
  512. (2006). Topiramate raises anterior cingulate cortex glutamine levels in healthy men; a 4.0 T magnetic resonance spectroscopy study. Psychopharmacology (Berl)
  513. (2007). Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebocontrolled study.
  514. (2004). Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist.
  515. (1997). Topiramate: a review of preclinical, pharmacokinetic, and clinical data.
  516. (1994). Topiramate: preclinical evaluation of structurally novel anticonvulsant.
  517. (1985). Topple A
  518. (1965). Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects.
  519. (1997). Trafficking between glia and neurons of TCA cycle intermediates and related metabolites.
  520. (2000). Transport of glutamate and other amino acids at the blood-brain barrier.
  521. (1999). Traynelis SF
  522. (2003). Trigeminal antinociception induced by bicuculline in the periaqueductal gray (PAG) is not affected by PAG P/Q-type calcium channel blockade in rat.
  523. (2001). Trigeminal nociception-induced cerebral Fos expression in the conscious rat.
  524. (1984). Trigeminal projections to supratentorial pial and dural blood vessels in cats demonstrated by horseradish peroxidase histochemistry.
  525. (1999). Trigeminovascular nociceptive transmission involves N-methylD-aspartate and non-N-methyl-D-aspartate glutamate receptors.
  526. (2000). Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.
  527. (1998). Ultrastructural analysis of NMDA, AMPA, and kainate receptors on unmyelinated and myelinated axons in the periphery.
  528. (2005). Unitary hypothesis for multiple triggers of the pain and strain of migraine.
  529. (2000). Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter.
  530. (1999). Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action.
  531. (1990). Vasoactive peptide release in the extracerebral circulation of humans during migraine headache.
  532. (1993). WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors.
  533. (1993). Widespread dopaminergic projections of the subparafascicular thalamic nucleus in the rat.
  534. (1994). Willardiines differentiate agonist binding sites for kainate- versus AMPA-preferring glutamate receptors in DRG and hippocampal neurons.
  535. (1989). Woda A

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.